Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
21 November 2023 - 2:00PM
Business Wire
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical
company focused on discovering and developing potential
best-in-class medicines for serious and rare diseases, today
announced that senior management will participate in a fireside
chat at the 6th Annual Evercore ISI HealthCONx Conference on
Thursday, November 30 at 11:15am ET in Miami, Florida.
A live webcast of the presentation can be accessed under “Events
and Presentations” on the Investors section of the Viridian website
at viridiantherapeutics.com. A replay of the webcast will be
available following the completion of the event.
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering
and developing potential best-in-class medicines for patients with
serious and rare diseases. Viridian’s expertise in antibody
discovery and engineering enables it to develop differentiated
therapeutic candidates for previously validated drug targets in
commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The company
is conducting two global Phase 3 clinical trials (THRIVE and
THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in
patients with active and chronic TED. Simultaneously, the company
is developing its subcutaneous program strategy with the goal of
providing a potentially more conveniently administered therapy to
patients with TED. In addition to its TED portfolio, Viridian is
advancing a novel portfolio of neonatal Fc receptor (FcRn)
inhibitors, VRDN-006 and VRDN-008, which has the potential to be
developed in multiple autoimmune diseases. Viridian is also
developing additional preclinical assets in autoimmune and rare
diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit www.viridiantherapeutics.com. Follow
Viridian on LinkedIn and X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231121247074/en/
Louisa Stone, 617-272-4604 Manager, Investor Relations
IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024